Therapix biosciences ltd. (TRPX)
CashFlow / Quarterly
Jun'18Jun'17
Net loss

-1,214

-1,863

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

3

1

Share-based payment expense

138

71

Finance expenses (incomes), net

422

-453

Profit loss

-281

525

Working capital adjustments:
Increase in accounts receivable

-50

-102

Decrease (increase) in trade payables

-101

-406

Decrease (increase) in other accounts payable

-189

-54

Working capital

-340

-562

Net cash used in operating activities

-1,835

-1,900

Cash flows from investing activities:
Increase in restricted cash

-

-2

Purchase of equipment

3

7

Grant of convertible loan

500

-

Net cash used in investing activities

-503

-9

Cash flows from financing activities:
Prepaid public offering costs

-1

-

Proceeds from issuance of share capital (net of issuance expenses)

-

1,943

Net cash provided by (used in) financing activities

1

1,943

Exchange rate differences on cash and cash equivalents in foreign currency

218

-453

Translation differences on cash and cash equivalents

-287

149

Increase (decrease) in cash

-2,406

-270